| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000037135 |
| Receipt No. | R000042323 |
| Scientific Title | Prospective voluntary clinical research that supports carbohydrate restriction and aerobic exercise and supports physical condition improvement for untreated patients who are pointed out hyperuricemia by medical checkups. |
| Date of disclosure of the study information | 2019/06/23 |
| Last modified on | 2019/06/22 (Ver. 1) |
| Basic information | ||
| Public title | Prospective voluntary clinical research that supports carbohydrate restriction and aerobic exercise and supports physical condition improvement for untreated patients who are pointed out hyperuricemia by medical checkups. | |
| Acronym | Prospective voluntary clinical research that supports carbohydrate restriction and aerobic exercise and supports physical condition improvement for untreated patients who are pointed out hyperuricemia by medical checkups. | |
| Scientific Title | Prospective voluntary clinical research that supports carbohydrate restriction and aerobic exercise and supports physical condition improvement for untreated patients who are pointed out hyperuricemia by medical checkups. | |
| Scientific Title:Acronym | Prospective clinical research that supports physical condition improvement for untreated hyperuricemia. | |
| Region |
|
|
| Condition | ||||
| Condition | Hyperuricemia | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | In this study, we will conduct carbohydrate restriction and appropriate aerobic exercise guidance interventions, and compare changes in uric acid levels with diet guidance alone. In addition, we examine each various factors how the intervention affecting the fluctuation of uric acid levels. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Amount of change in UA value at study start and 6 months after |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Single blind -participants are blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Educational,Counseling,Training | |
| Type of intervention |
|
|
| Interventions/Control_1 | (1)Conventional dietary guidance only group
|
|
| Interventions/Control_2 | (2)Aerobic exercise group after intiatinon of carbohydrate restriction diet
|
|
| Interventions/Control_3 | (3)Carbohydrate restriction after initiation of aerobic exercise | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Target patients who meet all the following criteria
1) Hyperuricemia patients (untreated patients: UA value 7 mg / dL or more) 2) Patients of 20 years or older at the time of obtaining consent (regardless of gender) 3) Patients who obtained written consent by their own free will after receiving sufficient explanation for participating in this study 4) Patients who have used smartphone usually and have a email address |
|||
| Key exclusion criteria | Patients who conflict with any of the following will not be included in this study
1) Patients who have already received drug treatment for hyperuricemia 2) Patients who received treatment for hyperuric acid treatment up to 3 months ago and have been discontinued. 3) Patients who have received medical treatment such as diabetes (including boundary type) 4) Patients with a history of myocardial infarction 5) Patients with a history of coronary revascularization (PCI or CABG) 6) Patients with unstable angina 7) Patients with a history of cerebrovascular disease (except asymptomatic lacunar infarction) 8) Patients who have been hospitalized for heart failure 9) Patients with severe liver disease (AST (GOT) or ALT (GPT)> 100 U) 10) Patients with severe renal disease (BUN 25 mg / dL or more or serum creatinine 2.0 mg / dL or more) 11) Pregnant and nursing women 12) Any patient who the research director has judged inappropriate as a research subject |
|||
| Target sample size | 500 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Sendai Tokushukai Hospital | ||||||
| Division name | orthopedic surgery | ||||||
| Zip code | 980-0011 | ||||||
| Address | 15 kagosawa nanakita ixumi-ku sendai city | ||||||
| TEL | 022-372-1110 | ||||||
| syoshida@miyagi.med.or.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Sendai Tokushukai Hospital | ||||||
| Division name | orthopedic surgery | ||||||
| Zip code | 980-0011 | ||||||
| Address | 15 kagosawa nanakita ixumi-ku sendai city | ||||||
| TEL | 022-372-1110 | ||||||
| Homepage URL | |||||||
| syoshida@miyagi.med.or.jp | |||||||
| Sponsor | |
| Institute | Sendai Tokushukai Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Sendai Tokushukai Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Sendai Tokushukai Hospital |
| Address | 15 kagosawa nanakita ixumi-ku sendai city |
| Tel | 022-372-1110 |
| syoshida@miyagi.med.or.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042323 |